Tactile Systems Technology vs Viemed Healthcare
TCMD and VMD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TCMD and VMD compare
Tactile Systems Technology is the larger company, worth 1.7 times as much as Viemed Healthcare ($590M against $345M).
On earnings, Viemed Healthcare is cheaper: it trades at 25.2× trailing earnings, against 25.3× for Tactile Systems Technology.
Viemed Healthcare grew revenue faster over the last twelve months (25.2% versus 14.4% for Tactile Systems Technology).
Tactile Systems Technology keeps more of each dollar of sales as profit, with a net margin of 6.7% compared with 4.8% at Viemed Healthcare.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TCMD | VMD |
|---|---|---|
| Size and price | ||
| Market cap | $590M | $345M |
| Share price | $26.05 | $9.07 |
| Change, 1 year | 9.9% | 41.9% |
| Change, 5 years | 26.0% | 73.4% |
| Beta (5Y) | 0.42 | −0.27 |
| Employees | 1,086 | 1,382 |
| StockData Score | ||
| Total score | 17 | 17 |
| Valuation score | 4 | 4 |
| Growth score | 3 | 5 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 25.3× | 25.2× (better) |
| P/S | 1.7× | 1.1× (better) |
| P/B | 2.6× | 2.4× (better) |
| EV/EBITDA | 12.7× | 8.9× (better) |
| P/FCF | 20.3× | 11.8× (better) |
| PEG | – | 0.78 |
| FCF yield | 4.9% | 8.5% (better) |
| Fair value | $26.36 | $10.82 |
| Margin of safety | 1.2% | 16.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.4% | 25.2% (better) |
| Revenue growth, 5Y average | 12.0% | 15.5% (better) |
| Net income growth (TTM) | 31.1% (better) | 3.7% |
| EPS growth (TTM) | 33.8% (better) | 5.9% |
| EPS growth, 5Y average | – | −13.9% |
| Profitability | ||
| Gross margin | 77.0% (better) | 57.5% |
| Operating margin | 9.4% (better) | 7.5% |
| Net margin | 6.7% (better) | 4.8% |
| FCF margin | 8.1% | 9.7% (better) |
| Return on equity | 11.0% (better) | 10.2% |
| Return on invested capital | 15.3% (better) | 12.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.05 (better) |
| Net debt / EBITDA | – | −0.09 |
| Interest coverage | 432× | – |
| Current ratio | 3.51 (better) | 1.13 |
| Altman Z-score | 7.95 (better) | 6.18 |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 2.1% | 5.3% (better) |
| Shareholder yield | 2.1% | 5.3% (better) |
| Ownership | ||
| Held by institutions | 96.7% | 71.3% |
| Held by insiders | 4.4% | 15.4% |
| Insider net buying, 12 months | −$2.3M | −$1.6M (better) |
| Short interest, % of float | 12.9% | 4.7% |
Go deeper
- TCMD stock overview
- TCMD income statement
- TCMD valuation and score
- VMD stock overview
- VMD income statement
- VMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.